anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Alexithymia is a trait involving difficulties in processing emotions. Genetic association studies have investigated candidate genes involved in alexithymia's pathogenesis. Therefore, the aim of the present study was to perform a systematic review of the genetic background associated with alexithymia.
METHODS: A systematic review of genetic studies of people with alexithymia was conducted. Electronic databases including PubMed, Scopus, and Web of Science were searched for the study purpose. We used the words "Alexithymia", "gene", "genetics", "variants", and "biomarkers". The present systematic review was performed following the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement. We found only candidate gene studies. A total of seventeen studies met the eligibility criteria, which comprised 22,361 individuals. The candidate genes associated with alexithymia were the serotoninergic pathway genes solute carrier family 6 member 4 (SLC6A4), serotonin 1A receptor (HTR1A), and serotonin 1A receptor (HTR2A); the neurotransmitter metabolism genes dopamine receptor D2 (DRD2), ankyrin repeat and kinase domain containing 1 (ANKK1), catechol-o-methyltransferase (COMT), brain-derived neurotrophic factor (BDNF), and oxytocin receptor (OXTR); and other pathway genes, vitamin D-binding protein (VDBP), tumor protein P53 regulated apoptosis inducing protein 1 (TP53AIP1), Rho GTPase Activating Protein 32 (ARHGAP32), and transmembrane protein 88B (TMEM88B).
CONCLUSION: The results of this study showed that only case-control gene studies have been performed in alexithymia. On the basis of our findings, the majority of alexithymia genes and polymorphisms in this study belong to the serotoninergic pathway and neurotransmitter metabolism genes. These data suggest a role of serotoninergic neurotransmission in alexithymia. Nevertheless, more and future research is required to learn about the role of these genes in alexithymia.
Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with heart failure or those patients undergoing renal dialysis (see PRECAUTIONS: Drug Interactions).

In heart failure, where the blood pressure was either normal or low, transient decreases in mean blood pressure greater than 20 percent were recorded in about half of the patients. This transient hypotension is more likely to occur after any of the first several doses and is usually well tolerated, producing either no symptoms or brief mild lightheadedness, although in rare instances it has been associated with arrhythmia or conduction defects. Hypotension was the reason for discontinuation of drug in 3.6 percent of patients with heart failure.

BECAUSE OF THE POTENTIAL FALL IN BLOOD PRESSURE IN THESE PATIENTS, THERAPY SHOULD BE STARTED UNDER VERY CLOSE MEDICAL SUPERVISION.

A starting dose of 6.25 or 12.5 mg t.i.d. may minimize the hypotensive effect. Patients should be followed closely for the first two weeks of treatment and whenever the dose of captopril and/or diuretic is increased. In patients with heart failure, reducing the dose of diuretic, if feasible, may minimize the fall in blood pressure.

Hypotension is not per se a reason to discontinue captopril. Some decrease of systemic blood pressure is a common and desirable observation upon initiation of captopril tablets treatment in heart failure. The magnitude of the decrease is greatest early in the course of treatment; this effect stabilizes within a week or two, and generally returns to pretreatment levels, without a decrease in therapeutic efficacy, within two months.
After completing the screening questionnaire and being evaluated, they receive TENS stimulation TENS stimulation in the luteal phase between days 17 to 24 of the menstrual cycle after the start of bleeding. They are evaluated again at the beginning of the next bleeding phase, being 7 days after the intervention, as well as 28 days after, being the next cycle.
The Self-perceived Barriers for Physical Activity Questionnaire (SBPAQ) is originally developed in Spanish to evaluate self-perceived barriers for physical activity participation in healthy individuals. The purpose of this study is to translate and cross-culturally adapt the SBPAQ into Turkish and investigate its psychometric properties. Approximately two hundred healthy individuals aged between 18-65 years will be included. For cross-cultural adaptation, two bi-lingual translators will use the back-translation procedure. After the questionnaire will be translated into Turkish, the reliability, validity, and internal consistency of the Turkish version of SBPAQ (SBPAQ-T) will be tested. The questionnaire will be applied twice within 7 days to evaluate the test-retest reliability and to calculate the "Intraclass Correlation Coefficient" (ICC). Pearson correlation coefficient will be used to analyze construct and convergent/divergent validity. The construct validity of SBPAQ-T will be analyzed based on its correlation with the Physical Activity Barriers Questionnaire, International Physical Activity Questionnaire-Short Form, and Short Form-12. The Cronbach's Alpha will be calculated to determine internal consistency. The level of significance is considered as 0.05. The floor and ceiling effects will be detected.
PCT No. PCT/JP94/02103 Sec. 371 Date Sep. 8, 1995 Sec. 102(e) Date Sep. 8, 1995 PCT Filed Dec. 12, 1994 PCT Pub. No. WO95/16362 PCT Pub. Date Jun. 22, 1995A process for preparing a product from a pulse crop as a starting material and a food containing the product prepared from a pulse crop as a starting material are disclosed according to the present invention, thereby enabling a food, a livestock feed, an aquacultural feed or the like to be efficiently prepared, which is made from a leguminous crop or a defatted product thereof or the like, which has excellent carcinopreventive and carcinostatic activities, osteoprosis therapeutic effect and immunosuppressive effect, and which can be ingested in a sufficient amount, and thereby enabling a wholesome food such as a biscuit having the above-mentioned excellent pharmacological activities. Any conventional product made from a pulse crop does not have such excellent pharmacological activities and a process for preparing the same is poor in efficiency. Significant characteristic feature of the present invention resides in that glycosidic saccharides are hydrolytically separated from isoflavone compounds contained in a pulse crop to form isoflavone compounds containing aglycones in a large amount and that phytic acid contained in a pulse crop is removed to obtain a product having excellent pharmacological activities.
GVHD prophylaxis will consist of high-dose PTCy (50 mg/kg i.v. on days +3 and +4) with mesna, cyclosporine (initiated on day +5) and methotrexate i.v (see doses on the right). Cyclosporine will be dosed with a target trough of 200 to 250 ng/mL and discontinued without taper at D+60 (if bone marrow graft) or until D+90 (is peripheral blood graft), unless acute GVHD is present. Filgrastim will be administered from day +5 until neutrophil recovery to ≥ 1,000/mcL for 3 days.
PROBLEM TO BE SOLVED: To obtain a bonding auxiliary for a denture base, capable of being readily coated when relining the denture base made from a polysulfone-based resin with a relining material made from an acrylic resin, capable of being readily coated, excellent in operating efficiency, surely bonding the relining material thereto and excellent in preservation stability by including a specific compound in methylene chloride. SOLUTION: This bonding auxiliary for a denture base is obtained by including 0.1-10 pts.wt. polycarbonate, 0.1-10 pts.wt. polymethyl methacrylate and 0.1-15 pts.wt. polyfunctional methacrylic ester based on 100 pts.wt. mthylene chloride. 2,2-Bis(4-methacryloxypolyethoxyphenyl)propane is most preferred as the polyfunctional methacrylic ester and 2,2,-bis(methacryloxyphenyl)propane, 2,2-bis[4-(2-hydroxy-3-methacryloxypropoxy)phenyl]propane, etc., are further cited. The ingredients can be used alone or by combining two or more thereof.
BACKGROUND & AIMS: Paracentesis is commonly used to manage patient discomfort due to ascites. The relationship between ascites pressure, ascites volume, and patient discomfort has not been elucidated.
METHODS: We prospectively enrolled adult patients with non-malignant ascites undergoing outpatient therapeutic paracenteses from 2021 to 2024 at a tertiary care hospital. Patients completed a validated symptom questionnaire (ASI-7, maximum score 35) before, immediately after, and 1 week after paracentesis. An open-ended manometer was used to measure ascites pressure at the beginning and end of paracentesis. Mixed effect linear regression was performed to evaluate the relationships between patient characteristics, pressure, volume, and symptoms.
RESULTS: One hundred and fifty paracentesis procedures among 48 unique patients with an average Model for End Stage Liver Disease-Sodium 3.0 of 16.7 were included. An average of 6.5 L was drained, which reduced abdominal pressure from a mean of 13.7 to 6.0 cm H2O (10.1 to 4.4 mmHg, p < 0.001) and mean symptom score from 22.6 to 6.5 (p < 0.001). Regression models identified that symptoms and abdominal pressure linearly correlated above a pressure of 6 cm H2O or ASI-7 score of 16 (p < 0.01). Taller patients required about 670 ml additional drainage per inch above the cohort mean height (5'8″) to achieve the same symptom relief.
CONCLUSIONS: Pressure measured at the bedside can be used to explore changes in abdominal pressure during paracentesis. Pressure, volume, and patient level factors such as height contribute to patient symptoms but cannot fully explain discomfort associated with ascites and relief after paracentesis.
Separation of target material from a liquid sample is achieved by coupling the target to targetable encapsulated gas microbubbles, allowing the microbubbles and coupled target to float to the surface of the sample to form a floating microbubble/target layer, and separating this layer from the sample. In a positive separation process the microbubbles are then removed from the target, e.g. by bursting. In a negative separation process target-free sample material is recovered following separation of the floating layer. The method may also be used diagnostically to detect the presence of a disease marker in a sample. Novel separation apparatus is also described.
Glaucoma therapy in patients with chronic open-angle (wide-angle) glaucoma should be monitored and may need to be adjusted during Transderm Scōp use, as the mydriatic effect of scopolamine may cause an increase in intraocular pressure.

Transderm Scōp should not be used in children and should be used with caution in the elderly. See PRECAUTIONS.

Since drowsiness, disorientation, and confusion may occur with the use of scopolamine, patients should be warned of the possibility and cautioned against engaging in activities that require mental alertness, such as driving a motor vehicle or operating dangerous machinery.

Rarely, idiosyncratic reactions may occur with ordinary therapeutic doses of scopolamine. The most serious of these that have been reported are: acute toxic psychosis, including confusion, agitation, rambling speech, hallucinations, paranoid behaviors, and delusions.
Cases enrolled between Jan 2000 and Apr 2004 at five locations. Study subject eligibility: Age \>=18; scheduled for radical prostatectomy; and newly diagnosed with localized prostate cancer.
A pet treat pocket is provided. The pet treat pocket includes a first pocket disposed on a top surface of a flexible member and a second pocket disposed on a lower surface of the flexible member. The pockets each define an interior volume sized to encapsulate a pill or liquid medication, respectively. An exterior length of each pocket is less than a length of the flexible member, and an exterior width of each pocket is less than a width of the flexible member such that the flexible member extends beyond the exterior dimensions of each pocket forming a lip surrounding a circumference of each pocket. The flexible member and the pockets are both composed of an ingestible and pet-safe material. The ingestible and pet-safe material can adhere to itself such that the flexible material can be molded to completely envelope the pockets and maintain a sealed configuration.
The present invention discloses a vitis plant extract, a preparation method thereof and new applications of the vitis plant extract used as an antibiotic synergistic agent. Grape fruits, grape roots, grape vines, grape leaves, grape peel and grape seeds are respectively separated, extracted and purified with a water extraction method, an alcohol extraction method and a glycerol extraction method for obtaining extracting solutions. Then, the respectively obtained extracting solutions are uniformly mixed, and finally, the respectively obtained extracting solutions are processed through concentration, drying, spray drying and freeze drying for obtaining a powdery extract containing one kind of effective components or multiple kinds of effective components. The present invention has raw materials which are easy to obtain, combines modern chemical techniques and biological techniques, and selects various extraction methods and separation methods according to the different parts of the vitis plants. The obtained extract has the many-sided medical care functions of cardiovascular circulation improvement, cerebrovascular circulation improvement, antioxidation, aging resistance, virus resistance, immunity enhancement, etc., and especially, people discover that the obtained extract has the function of bacterial medicine resistance elimination. When used by being matched with antibacterial medicine, the obtained extract can markedly enhance the curative effects of the antibacterial medicine.
PURPOSE:To easily and conveniently prepare a bioabsorbable polyester contg. only small amts. of unreacted monomers and low-mol.wt. volatiles by treating the polymn. system of glycolide or lactide kept in a molten state under a reduced pressure in the latter half stage of or after the completion of the polymn. CONSTITUTION:In producing a bioabsorbable polyether contg. repeating units of the formula (wherein R1 and R2 are each H or CH3) by the reaction of glycolide and/or lactide, the polymn system is treated under a reduced pressure (pref. 5mmHg or lower) in the latter half stage of or after the completion of the polymn. while keeping the resulting polymer in a molten state. Thus, the bioabsorbable polyester contg. only small amts. of unreacted monomers and low-mol.wt. volatiles is easily and conveniently produced.
The invention discloses a recombinant protein expressed by SARS-CoV-2 virus S protein receptor binding region coding gene, an antibody produced by the recombinant protein and application thereof, belonging to the fields of biomedicine and immunological detection. The coding gene has the nucleotide sequence shown in SEQ ID NO: 2. The coding gene or the antibody can be applied to preparing and detecting the antibody of the S protein receptor binding region of the SARS-CoV-2 virus. The invention discloses an antibody prepared by using recombinant protein expressed by the coding gene and application thereof. The coding gene of the invention ensures the uniqueness of protein expression and reduces the difficulty of subsequent purification of protein. The prepared antibody has high sensitivity and strong specificity for detecting the antigen.
Patients with PIK3CA mutation without RAS mutation or PTEN loss receive taselisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
PURPOSE:To obtain a platelet aggregation suppressing agent containing isoliquiritigenin as an active ingredient, having platelet aggregation suppressing action and useful in remedy for thrombotic disease. CONSTITUTION:Isoliquiritigenin expressed by the formula and contained in Glycyrrhizac Radix of crude drug is contained as an active ingredient. Isoliquiritigenin is obtained by condensing resacetophenone with p- hydroxybenzaldehyde. Isoliquiritigenin can be administered to animal and person directly or together with a common pharmaceutical carrier. The administer form is not especially limited and the agent is normally and preferably administered at an amount of 60-600mg (as wt. of isoliquiritigenin) per adult daily several times, e.g., so as to exhibit expected effect as a oral agent.
PURPOSE: A (2'S)-columbianetin compound isolated from Corydalis heterocarpa, and a cosmetic composition containing the same are provided to ensure excellent photoprotective, antioxidative, and anti-aging effects. CONSTITUTION: A (2'S)-columbianetin compound isolated from Corydalis heterocarpa is denoted by chemical formula 1. A method for preparing the compound of chemical formula 1 comprises: a step of extracting Corydalis heterocarpa with MeOH and CH_2Cl_2; a step of evaporating the extract by a reduced pressure, and fractioning with methanol; and a step of isolating the compound from the fraction. A photoprotective cosmetic composition contains (2'S)-columbianetin of chemical formula 1. A cosmetic composition for anti-aging contains the compound of chemical formula 1. A pharmaceutical composition for preventing or treating dermatitis contains the compound of chemical formula 1.
Fibrosing interstitial lung diseases (FILDs) other than idiopathic pulmonary fibrosis (IPF) can develop into progressive pulmonary fibrosis (PPF) despite initial management. A substantial proportion of patients with non-IPF interstitial lung diseases (ILDs) progress to PPF, including connective tissue disease-associated ILD (such as rheumatoid arthritis-associated ILD, systemic sclerosis-associated ILD, and idiopathic inflammatory myositis-associated ILD), fibrosing hypersensitivity pneumonitis, and fibrosing occupational ILD. The concept of PPF emerged only recently and several studies have confirmed the impact of PPF on mortality. In addition to poor prognosis among patients with PPF, there remains a lack of consensus in the diagnosis and treatment of PPF across different types of ILDs. There is a need to raise awareness of PPF in FILDs and to explore measures to improve PPF diagnosis and treatment, which in turn could potentially reduce the progression from FILD to PPF. This review discusses the disease burden of PPF and recent advances in the management of PPF among patients with ILDs, including antifibrotic medications that have emerged as promising treatment options. Additionally, this review highlights the perspectives of expert Chinese physicians with regard to their experience in managing PPF in clinical practice.
The control condition participants are assigned to the standard substance abuse education program which is delivered in a classroom format format. They will meet for 10 weekly 50 minute classroom sessions.
Client participants of counselors who were randomized to the experimental condition will receive the following intervention: The online Navigating my Journey relapse prevention program is an adjunct to outpatient treatment. We will ask client participants to complete at least 12 Navigating my Journey sessions and discuss them with their counselors.
This non-randomized, open-label, single center phase II study, will determine if patients with advanced oral tongue cancer that are treated with induction doses of cetuximab followed by treatment with radiation therapy concurrently with cetuximab and cisplatin (when indicated by positive margins or extra-capsular extension), will have improved PFS and improved survival and feasible toxicity, compared with patients treated in previous clinical trials (RTOG 9501 and EORTC 22931) with standard therapy: radiotherapy of 60 Gy with or without a 6-Gy boost (RTOG 9501) or 66 Gy (EORTC 22931) delivered through a conventional fractionation regimen of five once-daily sessions per week, and cisplatin in a dose of 100 mg/m2 on days 1, 22, and 43.. Twenty five patients will be recruited. Cetuximab treatment will be started (day 0) with 400 mg/m2 followed by two doses of 250 mg/m2 (once weekly on day 7 and 14). Surgery will be performed on day 31 followed by treatment with radiation therapy concurrently with cetuximab (250 mg/m2, once weekly) and cisplatin 35 mg/m2 (days 70-112; when indicated by positive margins or lymph nodes with extra-capsular extension). PET-CT and biopsies will be performed before starting with cetuximab, just before surgery and after chemo-cetuximab-RT to determine efficacy of treatment, and to compare the diagnostic properties of the PET-CT with that of the biopsies. The changes, before and after treatment with cetuximab, of protein levels in saliva, and tumor tissue and of microRNA levels in tumor tissue will be studied and correlated with PFS. The quality of life will be assessed. Data from clinical trials RTOG 9501 and EORTC 22931 will be used as historical controls.
OBJECTIVE: To enhance the accuracy in predicting lymph node metastasis (LNM) preoperatively in patients with papillary thyroid microcarcinoma (PTMC), refining the "low-risk" classification for tailored treatment strategies.
METHODS: This study involves the development and validation of a predictive model using a cohort of 1004 patients with PTMC undergoing thyroidectomy along with central neck dissection. The data was divided into a training cohort (n = 702) and a validation cohort (n = 302). Multivariate logistic regression identified independent LNM predictors in PTMC, leading to the construction of a predictive nomogram model. The model's performance was assessed through ROC analysis, calibration curve analysis, and decision curve analysis.
RESULTS: Identified LNM predictors in PTMC included age, tumor maximum diameter, nodule-capsule distance, capsular contact length, bilateral suspicious lesions, absence of the lymphatic hilum, microcalcification, and sex. Especially, tumors larger than 7 mm, nodules closer to the capsule (less than 3 mm), and longer capsular contact lengths (more than 1 mm) showed higher LNM rates. The model exhibited AUCs of 0.733 and 0.771 in the training and validation cohorts respectively, alongside superior calibration and clinical utility.
CONCLUSION: This study proposes and substantiates a preoperative predictive model for LNM in patients with PTMC, honing the precision of "low-risk" categorization. This model furnishes clinicians with an invaluable tool for individualized treatment approach, ensuring better management of patients who might be proposed observation or ablative options in the absence of such predictive information.
Participants in the Treatment as Usual (TAU) group will not receive Prolonged Exposure therapy, but will instead receive the standard clinical treatment received by all persons with spinal cord injury (SCI) at the rehabilitation facility. TAU participants will complete questionnaires/interviews at 1, 3, and 6 months from Baseline.